3.890USD-4.19%Mkt Cap: 237.13M USDP/E: —Last update: 2026-05-26
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap237.13M USD
Enterprise Value176.73M USD
Revenue (TTM)32.72M USD
Gross Profit33.29M USD
Net Income (TTM)-52.70M USD
Revenue/Share0.6070 USD
Last Price3.890 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees86
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.76
PEG—
EV/EBITDA-3.23
EV/Revenue5.40
P/S7.50
P/B4.37
EPS (TTM)-0.95
EPS (Forward)-1.48
52W Range
2.20052% of range5.424
52W High5.424 USD
52W Low2.200 USD
Profitability
Gross Margin99.43%
Oper. Margin-20069.09%
EBITDA Margin-166.94%
Profit Margin-157.40%
ROE-98.38%
ROA-45.88%
Growth
Revenue Growth-87.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-48.96M USD
CapEx (TTM)489.00K USD
FCF Margin-79.31%
FCF Yield-10.95%
Net Debt-78.55M USD
Net Debt/EBITDA1.44
Balance Sheet
Debt/Equity0.30
Current Ratio7.03
Quick Ratio6.90
Book Value/Sh0.9390 USD
Cash/Share1.576 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)12.29 USD
Target Range9.000 USD – 20.00 USD
# Analysts7
Ownership
Shares Out.59.88M
Float33.55M
Insiders26.23%
Institutions41.66%
Short Interest
Short Ratio6.3d
Short % Float2.64%
Short % Out.1.62%
Shares Short972.59K
Short (prev mo.)957.94K
Technical
SMA 504.232 (-8.1%)
SMA 2003.841 (+1.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)232.71K
Avg Vol (10d)307.25K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—